A randomized phase II study of paclitaxel alone versus paclitaxel plus sorafenib in second- and third-line treatment of patients with HER2-negative metastatic breast cancer (PASO).
| Image |  |
|---|---|
| Description | scientific article |
| Author/s |
author: Tanja Trarbach Jörg Sahlmann |
| Publication date | July 25, 2017 |
| Language | English |
| Country of origin | |
| Wikipedia link | |
| Copyright status | |
| Missing/wrong data? | Edit Wikidata item |